Seres Therapeutics said Memorial Sloan Kettering collaborators will present Phase 1b data at SITC 2026 showing SER-155 achieved an 80% immunosuppressive-free cl

BWB News TV • 2026-11-06 13:37 UTC • By Billy Odell Tucker-Robinson

Seres Therapeutics said Memorial Sloan Kettering collaborators will present Phase 1b data at SITC 2026 showing SER-155 achieved an 80% immunosuppressive-free clinical response in immunotherapy-related enterocolitis, with 12 of 15 patients responding.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly